The Pharmacy Times® Neurology resource center provides clinical news and articles, information about upcoming conferences and meetings, updated clinical trial listings, and other resources.
What can we help you find?
There were a number of FDA approvals in 2019 that were either the first new therapies or first in class approved for certain conditions, and the specialty pipeline is continuing to grow at a rapid pace.
In the face of the COVID-19 pandemic, neurologists are concerned that immunosuppressive treatments for multiple sclerosis and other disorders have significant risks.
An investigational drug for treating amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, has been shown to slow the progression of the disease.
There is a new study that discovered certain drugs cause problems in healthy people who do not have risk factors or family members with dementia.
Researchers Find Pandemic Has Had Little Emotional Impact on Patients with Progressive Multiple Sclerosis
Research suggests that those with progressive multiple sclerosis may have adjusted more effectively to lockdown conditions.
Although there is no underlying mechanism specifically associating cognitive and visual impairment, the investigators noted that the relationship between cognitive and visual function is likely bidirectional and multifactorial.
Post-menopausal women are at a heightened risk of Alzheimer disease.
Individuals with a higher risk of cardiovascular disease (CVD) demonstrate an increase in cognitive decline, including a rise in the typical markers of Alzheimer disease, according to the results of a recent study.
Flavonoids are natural substances found in plants, including fruits and vegetables, and are associated with various health benefits, such as reduced inflammation.
Contrary to previous studies, the rate of cognitive impairment has increased over the past 20 years.
The FDA has approved Nurtec ODT (rimegepant) from Biohaven Pharmaceuticals to treat acute migraines with or without aura in adults.
A new medication for certain rare blood cancers has now become available through a limited distribution with AllianceRx Walgreens Prime.